WithdrawnPhase 1
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Key facts
- Who runs it
- Jeremy Rudnick, M.D
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- Jun 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- Activated T cells
- Record updated
- 22 October 2025
- Why it stopped
- Lack of Funding
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Recurrent glioblastoma
- HLA-A1 and HLA-A2 positive
- Complete resection of tumor
Who cannot take part
- Presence of an acute infection requiring active treatment with antibiotics/antivirals; prophylactic administration is allowed
- Clinically significant pulmonary, cardiac or other systemic disease
- Known human immunodeficiency virus positivity or acquired immunodeficiency syndrome related illness or other serious medical condition
- Known history of Hepatitis B or Hepatitis C
- Allergy to Dimethyl sulfoxide (DMSO)
- Allergy to gentamicin
Where in United States
- Cedars-Sinai Medical CenterLos Angeles, United StatesNo longer taking part
About the trial
What the trial wants to find out
The purpose of this study is to examine the use of activated T cells (ATCs) to assess the safety and tolerability of autologous activated T cells, as measured by the number of Grade 3 or higher toxicities, the number of serious adverse events, and treatment-related toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of overall survival, rate of progression-free survival, health-related quality of life parameters, overall response rate, immune response, and tumor stem cell antigen expression.
The group in the trial
- Activated T cellsTreatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase I Trial of Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
- Record updated
- 22 October 2025